Показать сокращенную информацию
dc.contributor.author | De Crescenzo F. | |
dc.contributor.author | Ziganshina L. | |
dc.contributor.author | Yudina E. | |
dc.contributor.author | Kaplan Y. | |
dc.contributor.author | Ciabattini M. | |
dc.contributor.author | Wei Y. | |
dc.contributor.author | Hoyle C. | |
dc.date.accessioned | 2019-01-22T20:53:22Z | |
dc.date.available | 2019-01-22T20:53:22Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/149275 | |
dc.description.abstract | © 2018 The Cochrane Collaboration. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of noradrenaline reuptake inhibitors (NRIs) compared with placebo or no treatment, or any active pharmacological control for treating attention deficit hyperactivity disorder (ADHD) in adults. | |
dc.title | Noradrenaline reuptake inhibitors (NRIs) for attention deficit hyperactivity disorder (ADHD) in adults | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 6 | |
dc.relation.ispartofseries-volume | 2018 | |
dc.collection | Публикации сотрудников КФУ | |
dc.source.id | SCOPUS-2018-2018-6-SID85048329954 |